 The study will enroll approximately 300 patients. Participants with body weight 20 kg will receive the recommended dose of leuprorelin 3.75 mg subcutaneous injection every 4 weeks for 96 weeks. Participants with body weight 20 kg will receive recommended dose of 1.88 mg subcutaneous injection every 4 weeks for 96 weeks. 